Hepatitis

Hepatitis is one of the harder service-connection cases to win, and the reason is structural. The rating itself, under 38 CFR § 4.114, DC 7354, is fairly mechanical once entitlement is established. The fight almost never lands on severity. It lands on whether the virus can be tied to something that happened in service. In Claim Raven's analysis of 499 BVA hepatitis cases, 58.1% were denied. That denial share is high for a reason, and the reason is the nexus question.

Hepatitis C in particular has a long latency. A veteran can be infected during service in the 1970s or 1980s and not develop symptoms or get a diagnosis until decades later. By then the file may show nothing connecting the infection to service. There is no presumptive pathway for hepatitis C the way there is for some other conditions, so every case rises or falls on a risk-factor analysis: air-gun (jet injector) immunizations at induction, blood exposure, combat medic duties, battlefield transfusions, shared personal-care or drug-use equipment, and the like. When that analysis is missing or thin, the claim gets denied.

This page walks through the current criteria, why DC 7354 now points to DC 7345, the treatment-based 100 percent tier and the weight-loss line that separates 40 from 60, the in-service risk-factor nexus that decides most of these cases, the C&P exam mechanics, the separate rating of sequelae like cirrhosis and liver cancer, and the evidence gaps I see across the BVA dataset.

TL;DR

• Hepatitis C (and non-A, non-B hepatitis) is rated under 38 CFR § 4.114, DC 7354. Chronic hepatitis B and chronic liver disease are rated under DC 7345.
• DC 7354 no longer carries criteria. Since 2024-05-19 it reads "Rate under DC 7345 (Chronic liver disease without cirrhosis)." The code stays 7354; the criteria are 7345's.
• The "incapacitating episodes" framework is gone. The old tiers turned on cumulative episode duration over 12 months, defined as acute symptoms requiring both bed rest and physician treatment. No version of that language survives in the current text, and severity disputes built on counting bed-rest weeks are arguing a repealed standard.
• The current tiers are 0, 20, 40, 60, and 100 percent. The 100 percent rung is defined by treatment (parenteral antiviral plus parenteral immunomodulatory therapy, and for six months after they stop), not by symptoms.
• The 40 and 60 percent tiers are identical except for "minor" versus "substantial" weight loss. Serial weights in the record are what separate them.
• The 20 percent tier needs only one symptom, and it may be intermittent: fatigue, malaise, anorexia, hepatomegaly, or pruritus. No medication or weight-loss requirement.
• The dominant battleground is not severity. It is the nexus: connecting the infection to an in-service risk factor such as air-gun immunizations, blood exposure, combat medic duties, transfusions, or shared equipment.
• There is no presumptive service connection for hepatitis C, so the claim depends on a documented risk factor plus a medical opinion linking it to the current infection.
• Sequelae such as cirrhosis and hepatocellular carcinoma are rated separately under the appropriate code rather than combined with DC 7354.
• In Claim Raven's analysis of 499 BVA hepatitis cases, 58.1% were denied, 19.4% were remanded, and 22.4% were granted. Of the 374 cases with a C&P adequacy determination, 43.3% had the exam flagged as inadequate.

DC 7354 Now Sends You to DC 7345

Hepatitis C, and non-A, non-B hepatitis, still has its own diagnostic code at 38 CFR § 4.114, DC 7354, but that code no longer carries criteria. Since the digestive-system rewrite published March 20, 2024 (89 FR 19735) and effective May 19, 2024, the entry reads in full:

7354 Hepatitis C (or non-A, non-B hepatitis): Rate under DC 7345 (Chronic liver disease without cirrhosis).

So the code on your decision may still read 7354, while the criteria being applied are DC 7345's. Those criteria were themselves rewritten, and the change is fundamental: the old "incapacitating episodes" framework is gone. If you are reading a guide built on episode durations of one, two, four, or six weeks over a 12-month period, it is describing the superseded rule.

Here is the current DC 7345 text:

Progressive chronic liver disease requiring use of both parenteral antiviral therapy (direct antiviral agents), and parenteral immunomodulatory therapy (interferon and other); and for six months following discontinuance of treatment, 100%

Progressive chronic liver disease requiring continuous medication and causing substantial weight loss and at least two of the following: (1) daily fatigue, (2) malaise, (3) anorexia, (4) hepatomegaly, (5) pruritus, and (6) arthralgia, 60%

Progressive chronic liver disease requiring continuous medication and causing minor weight loss and at least two of the following: (1) daily fatigue, (2) malaise, (3) anorexia, (4) hepatomegaly, (5) pruritus, and (6) arthralgia, 40%

Chronic liver disease with at least one of the following: (1) intermittent fatigue, (2) malaise, (3) anorexia, (4) hepatomegaly, or (5) pruritus, 20%

Previous history of liver disease, currently asymptomatic, 0%

Three structural points follow, and they change how a claim should be built.

Treatment is now the top of the ladder. The 100 percent tier is not a symptom description at all. It is a treatment description: parenteral antiviral therapy and parenteral immunomodulatory therapy, both, plus six months after they stop. Note (1) makes that explicit and requires a mandatory VA examination at the end of that six months, with § 3.105(e) protections applying to any reduction that follows. A veteran on that regimen should be at 100 percent while it runs, and should expect a scheduled re-examination afterward.

The middle of the ladder splits on weight loss. The 60 and 40 percent tiers are the same sentence except for one word: "substantial" weight loss versus "minor" weight loss. Both require continuous medication and both require two or more from the same six-item list. So the documented weight trend is the single fact separating a 40 from a 60, which makes serial weights in the record unusually valuable on this claim.

The 20 percent tier is much easier to reach than it looks. It requires chronic liver disease with at least one of intermittent fatigue, malaise, anorexia, hepatomegaly, or pruritus. One symptom, and it can be intermittent. There is no medication requirement and no weight-loss requirement at this rung. Veterans who assume a controlled hepatitis diagnosis is worth nothing are frequently describing a 20 percent picture.

Two more notes matter. Note (2) provides that where physicians recommend both parenteral antiviral therapy and parenteral immunomodulatory drugs but treatment is medically contraindicated, VA rates under DC 7312 (cirrhosis of the liver) instead. Note (4) directs that sequelae such as cirrhosis or liver malignancy be rated under their own codes, but bars using the same signs and symptoms twice, per § 4.14.

A veteran whose hepatitis C has been cured by direct-acting antiviral therapy presents a separate problem, and the current text handles it more clearly than the old one did. The 0 percent tier is "previous history of liver disease, currently asymptomatic." Once the virus is cleared and symptoms resolve, that is the rung the schedule points to. Cure does not erase a service-connected diagnosis, and it does not foreclose a compensable rating where a qualifying symptom persists, since the 20 percent tier needs only one intermittent symptom. But residual liver damage and sequelae have to be documented on their own terms under Note (4).

What an "Incapacitating Episode" Actually Means

Under the pre-2024 rule the incapacitating-episode path was where most severity arguments were won or lost, on a narrow definition requiring both bed rest and physician treatment. That path no longer exists. What follows describes it because most published hepatitis case law still turns on it, and because claims covering periods before May 19, 2024 are still evaluated under it.

Both elements matter. Bed rest alone is not enough. Treatment by a physician alone is not enough. The episode has to involve both, and it has to be documented. A veteran who feels exhausted and stays in bed for a week without seeing a doctor has not, under the regulation as written, had an incapacitating episode that counts toward the duration tiers. Conversely, a routine follow-up visit where the veteran is functioning normally does not count either.

This is the single most common severity trap in hepatitis claims. The veteran genuinely experiences debilitating fatigue, nausea, and right upper quadrant pain for weeks at a time, but the medical record does not tie those weeks to physician-ordered or physician-documented bed rest. The rater then has no factual basis to count the time toward the six-week, four-week, or two-week thresholds, and the rating lands lower than the lived severity.

The fix is contemporaneous documentation. A treatment note that says "advised bed rest" or "unable to work, instructed to rest" during a symptomatic flare, paired with the physician's involvement in treatment, is the kind of entry that supports the incapacitating-episode count. Symptom journals that log the dates and duration of flares, cross-referenced against medical visits, help the examiner and the rater reconstruct the 12-month picture instead of guessing at it.

DC 7354 Versus DC 7345: Which Code Applies

Not all hepatitis is rated under DC 7354. The diagnostic code depends on the type of hepatitis and the underlying liver pathology.

DC 7354 covers hepatitis C and non-A, non-B hepatitis. Chronic hepatitis B and chronic liver disease without cirrhosis are rated under DC 7345. The two codes use similar symptom-and-incapacitating-episode logic, but they are distinct codes and they apply to distinct conditions. Getting the wrong code into a decision can produce a rating that does not match the diagnosis.

The practical point for a veteran: the type of hepatitis matters, and the serology in the record should be clear about it. A diagnosis of "hepatitis" without specifying B versus C, or without distinguishing acute from chronic, invites a rating analysis that misses the right code. If the record establishes chronic hepatitis B, the analysis should run through DC 7345, not DC 7354.

Where the liver has progressed to cirrhosis or cancer, neither 7354 nor 7345 is the end of the analysis. Those sequelae get rated separately, which is the subject of a later section.

The Nexus Fight: In-Service Risk Factors

This is the part of the hepatitis claim that decides most cases. With a 58.1% denial rate across the BVA cases in Claim Raven's dataset, the dominant failure mode is not a low severity rating, it is no service connection at all. Hepatitis C has no presumptive pathway, so the veteran has to show a current diagnosis, an in-service event or risk factor, and a medical nexus linking the two.

The recognized in-service risk factors that show up in BVA hepatitis decisions include:

Air-gun (jet injector) immunizations. For decades the military administered vaccinations with jet injectors that pressed against the skin in rapid succession across formations of service members. The concern is that contaminated injectors could transmit blood-borne virus between recipients. VA has acknowledged jet-injector immunization as a possible, biologically plausible mode of hepatitis C transmission, though it remains a contested and fact-specific theory rather than an automatic grant. A veteran who received jet-injector immunizations at induction, and who lacks other risk factors, has a recognized theory to develop.

Blood exposure. Combat wounds, exposure to others' blood, and handling of casualties create documented blood-borne exposure. This is one of the stronger risk-factor narratives when the service record supports it.

Combat medic and corpsman duties. Medics, corpsmen, and others who handled blood, started IVs, or treated wounds in the field have an occupational exposure pathway that is well recognized.

Transfusions. Battlefield or in-service transfusions, particularly before reliable hepatitis C screening of the blood supply, are a recognized risk factor.

Shared equipment. Shared razors, shared needles, tattoos received in service, and similar exposures appear in the case law. These are more fact-sensitive and can cut both ways, because VA may also point to them as non-service or post-service risk factors.

The nexus opinion is where these risk factors turn into a grant. A bare statement that the veteran "could have" contracted hepatitis C from a jet injector is not enough. The probative opinion identifies the in-service risk factor, weighs it against any competing post-service risk factors (intravenous drug use, post-service transfusions, high-risk exposures), and explains why the in-service factor is at least as likely as not the source. When the opinion addresses and rules out the competing causes, it carries far more weight than one that ignores them.

The high denial share connects directly to this. When the C&P examiner does not perform a real risk-factor analysis, or addresses only one factor and ignores the rest, or fails to weigh competing causes, the resulting opinion is weak. A weak or incomplete nexus opinion is exactly the kind of record that produces a denial at the RO and, on appeal, a remand for a better exam.

C&P Exam Mechanics: What the Examiner Has to Do

The hepatitis C&P exam follows the DBQ for hepatitis, cirrhosis, and other liver conditions. Two parts of that exam matter most, and they map onto the two fights described above.

For the nexus question, the examiner is supposed to take a full risk-factor history covering both in-service and post-service exposures, review the service treatment records and personnel file for documented risk factors, and provide an opinion that weighs the in-service factors against competing causes. An exam that records "veteran has hepatitis C" and offers a conclusory negative opinion without working through the risk factors is the kind of exam the Board sends back.

For the severity question under the current criteria, the examiner records which of the six named findings are present (daily fatigue, malaise, anorexia, hepatomegaly, pruritus, arthralgia), the weight trend and whether any loss is minor or substantial, whether the veteran is on continuous medication, and whether parenteral antiviral and immunomodulatory therapy is or was in use and when it stopped. Liver function tests, viral load, and any imaging or biopsy results round out the picture. Whether the virus has been treated and cleared by antiviral therapy is a material fact the examiner should address, because it changes the forward-looking disability.

Of the 374 hepatitis cases in Claim Raven's dataset that carried a C&P adequacy determination, 43.3% had the exam flagged as inadequate. That is a high inadequacy share, and it is consistent with the nexus dynamic: the most common inadequacy in these cases is a nexus opinion that does not actually analyze the risk factors. When the exam is inadequate, the Board's standard move is a remand for a corrected exam rather than an outright grant or denial, which is why the remand share in this subset is meaningful even though grants are the minority outcome.

Cirrhosis, Liver Cancer, and Separate Ratings for Sequelae

Hepatitis can progress. Chronic infection can lead to cirrhosis, and cirrhosis raises the risk of hepatocellular carcinoma. These sequelae are not folded into the DC 7354 rating. They are rated separately under the appropriate diagnostic code.

That matters for two reasons. First, it can substantially raise the combined rating. A veteran with active hepatitis C symptoms rated under DC 7354 and separately documented cirrhosis rated under its own code can carry a meaningfully higher combined evaluation than the hepatitis rating alone would suggest. Second, it shifts the evidentiary focus. The sequela has to be documented as a distinct diagnosis with its own clinical findings, and the service-connection chain for the sequela flows through the underlying service-connected hepatitis under 38 CFR § 3.310, which provides for secondary service connection for conditions caused or aggravated by a service-connected condition (Allen v. Brown).

The pyramiding rule under 38 CFR § 4.14 still applies. The same symptom cannot be rated twice. But cirrhosis and active hepatitis are different pathologies with different rating criteria, so a properly documented record can support separate evaluations rather than collapsing everything into one code. The key is that the record establishes each condition as a distinct diagnosis with its own findings.

Common Evidence Gaps in Hepatitis Claims

A few patterns I see across BVA decisions involving hepatitis.

No risk-factor narrative in the file. This is the central gap. The veteran has a confirmed hepatitis C diagnosis, but nothing in the record connects it to service. No statement about jet-injector immunizations, no account of blood exposure, no medic duties documented, no transfusion history. Without a stated in-service risk factor, the examiner has nothing to opine on and the claim defaults to denial. The veteran's own detailed statement about in-service exposures is often the missing piece that opens the case.

Nexus opinion that ignores competing causes. When an opinion does exist, it frequently fails by addressing the in-service factor in isolation while ignoring post-service risk factors, or by dismissing the in-service factor without explaining why a competing cause is more likely. An opinion that does not weigh the alternatives is not probative, and the Board says so on remand.

Incapacitating episodes not documented as such. On the severity side, the most common gap is a symptomatic veteran whose flares were never tied to physician-documented bed rest. The lived severity is real, but the record does not satisfy the bed-rest-plus-physician definition, so the duration tiers do not get applied. Contemporaneous treatment notes and symptom logs are what close this gap.

Sequelae left unrated. Cirrhosis or liver cancer present in the record but not separately claimed or rated. The hepatitis gets a rating and the downstream liver damage, which can carry its own evaluation, never enters the analysis.

Type of hepatitis unclear in the record. A diagnosis of "hepatitis" without clear serology distinguishing B from C, or acute from chronic, can push the claim into the wrong diagnostic code or leave the rater uncertain which criteria to apply.

I don't know the exact percentage of hepatitis claims that carry any one of these gaps. What I can say from Claim Raven's analysis of 499 BVA hepatitis cases is that 58.1% were denied, 19.4% were remanded, and 22.4% were granted, and that of the 374 cases with a C&P adequacy determination, 43.3% had the exam flagged as inadequate. That denial-heavy distribution, paired with a high exam-inadequacy share, is the statistical fingerprint of a nexus problem rather than a severity problem. The cases that succeed at the Board tend to have a clear, documented in-service risk factor and a nexus opinion that actually weighs it against the alternatives, not just a confirmed diagnosis.

What to Push For

For the nexus, the goal is a complete risk-factor record before the C&P exam, not after the denial. That means a detailed lay statement describing every plausible in-service exposure (jet-injector immunizations at induction, blood contact, medic or corpsman duties, transfusions, shared equipment), service records that corroborate where possible, and buddy statements from fellow service members who witnessed the exposures. With that record in hand, the examiner has the facts to perform a real risk-factor analysis, and the opinion can address competing post-service causes directly instead of defaulting to "etiology unclear."

For severity under the current criteria, the goal is to establish which named findings are present and what the weight has done. A symptom tracker for hepatitis flares that logs which of the six findings occur and how often still helps, but the highest-value records are serial weights and the medication history, because those are the facts the 40, 60, and 100 percent tiers are written around.

When a decision denies service connection on a thin or one-sided nexus opinion, the next step is to attack the adequacy of that opinion and supply the missing risk-factor evidence. An evidence checklist for hepatitis claims should separate the diagnosis, the in-service risk factor, the nexus opinion, and the severity documentation into their own proof lanes.

What to Ask the C&P Examiner to Address

The hepatitis exam is doing double duty: it has to support both the nexus and the severity rating. On the nexus, the examiner should take a full in-service and post-service risk-factor history, review the service records, and provide an opinion that identifies the in-service risk factor and weighs it against competing causes with a stated rationale. A conclusory opinion that does not work through the risk factors is the kind of exam that gets remanded.

On severity, the examiner should record which of the six named findings are present, the weight trend and whether loss is minor or substantial, whether continuous medication is required, whether parenteral antiviral and immunomodulatory therapy is in use, and whether the virus has been cleared by antiviral therapy. Use C&P exam prep for the hepatitis DBQ and bring documentation of flares and treatment so the examiner has facts to record rather than a single-day snapshot.

The exam is the engine. If the examiner skips the risk-factor analysis, the nexus becomes an appeal issue instead of evidence in the initial decision. If the examiner does not record the named findings and the weight trend, the severity rating lands lower than the lived disability.

Bottom Line

Hepatitis claims are not primarily a rating problem. The DC 7354 criteria are mechanical once entitlement is established, and they turn on the frequency of symptoms and the documented duration of incapacitating episodes. The reason 58.1% of the BVA hepatitis cases in Claim Raven's dataset were denied is the nexus: hepatitis C has no presumptive pathway, latency is long, and the claim lives or dies on whether the record ties the infection to an in-service risk factor like jet-injector immunizations, blood exposure, medic duties, transfusions, or shared equipment. The cases that win have a documented risk factor and a nexus opinion that weighs it against competing causes. The cases that lose, and most do, have a confirmed diagnosis and nothing connecting it to service. Same virus, different paper trail, different outcome. On severity, the second fight is documenting incapacitating episodes the way the regulation defines them, bed rest plus physician treatment, so the duration tiers actually get applied, and rating any cirrhosis or liver cancer separately rather than leaving the downstream damage out of the analysis.

Related Conditions

Hepatitis claims share rating and proof logic with other systemic and organ conditions. The secondary and severity dynamics overlap with kidney disease, where organ-function documentation and separate rating of complications matter, and with diabetes, another systemic condition where the nexus and the downstream complications drive the combined rating. Veterans with hepatitis that has progressed to liver damage should review the secondary conditions tool before assuming the hepatitis rating alone tells the whole story.

Methodology and Limitations

• Data source: Rating criteria quoted verbatim from the current 38 CFR § 4.114 as amended by the final rule "Schedule for Rating Disabilities: The Digestive System," 89 FR 19735, published 2024-03-20, effective 2024-05-19. DC 7354 (hepatitis C and non-A, non-B hepatitis) now directs "Rate under DC 7345 (Chronic liver disease without cirrhosis)," so the tier text quoted here is DC 7345's. Per Note (3) to DC 7345, hepatitis B is also evaluated there, and hepatitis C is tracked under DC 7354 while being evaluated on DC 7345's criteria. Pyramiding from § 4.14. Secondary service connection from § 3.310. Case law from Allen v. Brown on secondary aggravation. Risk-factor framework drawn from VA's recognized hepatitis C transmission modes and the BVA case law applying them.
• Sample size: Patterns in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from the analyzed subset of Claim Raven's 501,000+ Board-decision library, including 499 hepatitis cases. Within that hepatitis subset, outcomes ran 58.1% denied (290 cases), 19.4% remanded (97 cases), and 22.4% granted (112 cases). Of the 374 cases that carried a C&P adequacy determination, 43.3% had the examination flagged as inadequate. The dataset captures overall outcome rather than a per-tier or per-diagnostic-code breakdown.
• Classification approach: Diagnostic code definitions drawn from the current regulatory text. The nexus and risk-factor analysis follows the recognized in-service exposure theories and the way the Board applies them. Severity analysis follows the current DC 7345 tiers; the incapacitating-episode discussion is retained only as history.
• Limitations:
• The 499 BVA decisions predate the criteria on this page. They were decided under the old DC 7354, whose tiers ran on cumulative incapacitating-episode duration. Their outcome and exam-adequacy rates describe that standard, not the current one. The nexus findings, which drive most of these cases, are unaffected by the rating-criteria change.
• The current criteria leave "substantial" versus "minor" weight loss undefined, and that single word is the line between 40 and 60 percent.
• Hepatitis C has no presumptive service-connection pathway. Every case turns on a fact-specific risk-factor and nexus analysis, so outcomes vary widely with the quality of the record.
• The jet-injector (air-gun) immunization theory is biologically plausible and recognized as a possible transmission mode, but it is contested and fact-specific, not an automatic grant.
• Direct-acting antiviral therapy now cures most hepatitis C. A cured infection can lower the forward-looking rating unless residual liver damage or sequelae are separately documented.
• Selection bias: BVA-level patterns reflect cases that appealed. Most hepatitis claims resolve at the RO level and are not in any BVA dataset.
• The high denial share reflects the nexus difficulty in appealed cases and should not be read as the grant rate for well-documented claims with a clear in-service risk factor.
• These observations reflect patterns from the regulatory text, case law, and BVA decisions. They are not predictions of individual outcomes.